Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are trading lower Thursday afternoon after the lupus-focused drugmaker posted fourth quarter earnings and raised expectations for continued growth in 2026. Here’s what investors need to know.Aurinia Pharmaceuticals stock is feeling bearish pressure. What’s pressuring AUPH stock?Lupkynis Sales Drive Full-Year GrowthThe company reported fourth-quarter 2025 adjusted earnings of 26 cents a share, beating analysts' consensus of 22 cents and surging from one cent a ...

For the full year ended Dec. 31, 2025, Aurinia reported total revenue of $283.1 million, up 20% from $235.1 million in 2024. Miller noted that 2024 revenue included a one-time $10 million milestone payment tied to LUPKYNIS regulatory approval in Japan; excluding that milestone, Aurinia said total revenue increased 26% year over year. Full-year net product sales of LUPKYNIS were $271.3 million, up 25% from $216.2 million in 2024.Aurinia posted net income of $210.8 million for the fourth quarter, compared wit ...

Aurinia Pharmaceuticals (NasdaqGM:AUPH) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsGreg Keenan - Chief Medical OfficerJoe Miller - CFOPeter Greenleaf - President and CEOSahil Dhingra - Senior Equity Research AssociateWill Sawicki - AssociateConference Call ParticipantsArthur He - AnalystDavid Martin - AnalystFarzin Haque - Senior Vice President and Biotechnology Equity Research AnalystOlivia Brayer - Senior Equity AnalystOperatorGood morning. Welcome to the Aurinia Pharmaceutica ...

Aurinia Pharmaceuticals (NasdaqGM:AUPH) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsGreg Keenan - Chief Medical OfficerJoe Miller - CFOPeter Greenleaf - President and CEOSahil Dhingra - Senior Equity Research AssociateWill Sawicki - AssociateConference Call ParticipantsArthur He - AnalystDavid Martin - AnalystFarzin Haque - Senior Vice President and Biotechnology Equity Research AnalystOlivia Brayer - Senior Equity AnalystOperatorGood morning. Welcome to the Aurinia Pharmaceutica ...

Aurinia Pharmaceuticals (NasdaqGM:AUPH) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker6Good morning. Welcome to the Aurinia Pharmaceuticals fourth quarter and full year 2025 conference call. Please be advised that a Q&A session will follow Aurinia's prepared remarks. We ask you please ask 1 question and 1 follow-up, then return to the queue. I'll now turn the call over to Peter Greenleaf, President and Chief Executive Officer of Aurinia. Peter, please go ahead.Speaker7Good morning. We want to t ...

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +25.79%. A quarter ago, it was expected that this biotechnology company would post earnings of $0.16 per share when it actually produced earnings of $0.23, delivering a surprise of +43.75%.Over the last fou ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________________________________ Form 10-K ___________________________________________________________________________________ ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_______ ...

Core Viewpoint - Aurinia Pharmaceuticals Inc. will report its financial results for the three and twelve months ended December 31, 2025, and provide a business update on February 26, 2026 [1] Financial Reporting - The financial results will cover both the three-month and twelve-month periods ending December 31, 2025 [1] - A webcast and conference call will be hosted by the management team on February 26, 2026, at 8:30 a.m. ET [1] Conference Call Details - The conference call can be accessed by dialing 877-407-8029 or +1 201-689-8029 [1] - A link to the webcast is provided for participants [1]

Core Viewpoint - Aurinia Pharmaceuticals (AUPH) is forming a bullish chart pattern despite broader market challenges, indicating strong potential for earnings growth, particularly with its Lupkynis medicine for Lupus Nephritis [1]. Company Summary - Aurinia Pharmaceuticals is recognized for its Lupkynis medicine, which leads the treatment market for Lupus Nephritis [1]. - The company has an impressive earnings growth potential of 1,854%, suggesting significant upside for investors [1]. Market Context - The broader stock market has faced difficulties, impacting many high-performing stocks, yet Aurinia is showing resilience [1]. - The article mentions the performance of other stocks, including Moderna and various medical newcomers, indicating a competitive landscape in the pharmaceutical sector [1].

Company Performance - Aurinia Pharmaceuticals (AUPH) has returned approximately 81.2% since the start of the calendar year, significantly outperforming the average gain of 8.2% for Medical stocks [4] - The Zacks Consensus Estimate for AUPH's full-year earnings has increased by 20.3% over the past 90 days, indicating improved analyst sentiment and a stronger earnings outlook [4] - Aurinia Pharmaceuticals is currently ranked 2 (Buy) in the Zacks Rank system, which emphasizes earnings estimates and revisions [3] Industry Comparison - Aurinia Pharmaceuticals is part of the Medical - Drugs industry, which includes 146 stocks and is currently ranked 70 in the Zacks Industry Rank, with an average gain of 9.4% this year [6] - In contrast, Cardinal Health (CAH), another Medical stock, has returned 75.5% since the beginning of the year and is part of the Medical - Dental Supplies industry, which is ranked 102 and has gained 13.3% [5][6] - The Medical group, which includes Aurinia Pharmaceuticals, is currently ranked 6 within the Zacks Sector Rank, which evaluates 16 different sector groups [2]